| Primary |
| Intravenous Catheter Management |
18.4% |
| Indwelling Catheter Management |
16.1% |
| Central Venous Catheterisation |
13.8% |
| Drug Use For Unknown Indication |
10.3% |
| Anticoagulant Therapy |
6.9% |
| Breast Cancer |
6.9% |
| Thrombosis Prophylaxis |
6.9% |
| Osteomyelitis |
3.4% |
| Toe Amputation |
3.4% |
| Cardiac Operation |
2.3% |
| Antibiotic Therapy |
1.1% |
| Hyperemesis Gravidarum |
1.1% |
| Infection Prophylaxis |
1.1% |
| Localised Infection |
1.1% |
| Malnutrition |
1.1% |
| Multiple Myeloma |
1.1% |
| Neoplasm Malignant |
1.1% |
| Neuroborreliosis |
1.1% |
| Preoperative Care |
1.1% |
| Staphylococcal Infection |
1.1% |
|
| Therapeutic Product Contamination |
20.7% |
| Pharmaceutical Product Complaint |
14.6% |
| Serratia Infection |
9.8% |
| Medication Error |
7.3% |
| Vomiting |
7.3% |
| Heparin-induced Thrombocytopenia |
4.9% |
| Fungal Infection |
3.7% |
| Skin Discolouration |
3.7% |
| Skin Infection |
3.7% |
| Diarrhoea |
2.4% |
| Dyspnoea |
2.4% |
| Nausea |
2.4% |
| Rash |
2.4% |
| Renal Failure |
2.4% |
| Serratia Bacteraemia |
2.4% |
| Stomach Discomfort |
2.4% |
| Thrombophlebitis Superficial |
2.4% |
| Tremor |
2.4% |
| Infection |
1.2% |
| Mesenteric Vein Thrombosis |
1.2% |
|
| Secondary |
| Product Used For Unknown Indication |
82.1% |
| Drug Use For Unknown Indication |
3.4% |
| Cardiac Operation |
2.3% |
| Deep Vein Thrombosis |
2.3% |
| Rash |
1.7% |
| Thrombosis Prophylaxis |
1.3% |
| Anticoagulant Therapy |
0.8% |
| Central Venous Catheterisation |
0.8% |
| Indwelling Catheter Management |
0.8% |
| Prophylaxis |
0.8% |
| Intravenous Catheter Management |
0.6% |
| Metastatic Carcinoma Of The Bladder |
0.6% |
| Malnutrition |
0.4% |
| Neoplasm Malignant |
0.4% |
| Therapeutic Procedure |
0.4% |
| Chemotherapy |
0.2% |
| Chest Pain |
0.2% |
| Flushing |
0.2% |
| Nausea |
0.2% |
| Osteomyelitis |
0.2% |
|
| Heparin-induced Thrombocytopenia |
17.5% |
| Pharmaceutical Product Complaint |
17.5% |
| Vomiting |
12.5% |
| Sepsis |
10.0% |
| Fungal Infection |
5.0% |
| Generalised Oedema |
5.0% |
| Stomach Discomfort |
5.0% |
| Therapeutic Product Contamination |
5.0% |
| Cardiac Output Decreased |
2.5% |
| Cholelithiasis |
2.5% |
| Dizziness |
2.5% |
| Medication Error |
2.5% |
| Pulmonary Embolism |
2.5% |
| Pyrexia |
2.5% |
| Thrombocytopenia |
2.5% |
| Treatment Failure |
2.5% |
| Venous Thrombosis |
2.5% |
|
| Concomitant |
| Product Used For Unknown Indication |
24.2% |
| Prophylaxis |
11.4% |
| Nausea |
8.8% |
| Acute Myeloid Leukaemia |
6.8% |
| Drug Use For Unknown Indication |
6.8% |
| Pain |
5.5% |
| Transitional Cell Carcinoma |
3.7% |
| Vomiting |
3.5% |
| Non-small Cell Lung Cancer |
3.2% |
| Infection Prophylaxis |
3.1% |
| Constipation |
2.9% |
| Supplementation Therapy |
2.8% |
| Hepatitis C |
2.6% |
| Multiple Myeloma |
2.6% |
| Blood Pressure |
2.5% |
| Breast Cancer |
2.3% |
| Hypertension |
2.0% |
| Anxiety |
1.8% |
| Hypercalcaemia Of Malignancy |
1.8% |
| Central Venous Catheterisation |
1.7% |
|
| Vomiting |
12.3% |
| Sepsis |
8.6% |
| Hepatic Enzyme Increased |
7.4% |
| Death |
6.2% |
| Fatigue |
6.2% |
| Pneumonia |
6.2% |
| Vasculitis |
6.2% |
| Diarrhoea |
4.9% |
| Rash |
4.9% |
| Rash Erythematous |
4.9% |
| Renal Failure Acute |
4.9% |
| Tremor |
4.9% |
| Anaemia |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Abdominal Pain |
2.5% |
| Brain Oedema |
2.5% |
| Caecitis |
2.5% |
| Cardiac Arrest |
2.5% |
| Confusional State |
2.5% |
| Fungaemia |
2.5% |
|
